Organization
Foster City, CA
8 abstracts
Abstract
Performance characteristics of a tissue-agnostic genome-wide methylome enrichment MRD assay for head and neck malignancies.Org: Princess Margaret Cancer Centre, University Health Network, Adela, Inc., Foster City, CA, Toronto, ON, Canada,
Abstract
Genomic alterations in DNA damage response (DDR) genes in HR+/HER2- metastatic breast cancer (mBC) and impact on clinical efficacy with sacituzumab govitecan (SG): Biomarker results from TROPICS-02 study.Org: David Geffen School of Medicine at UCLA, University of California Irvine, Jonsson Comprehensive Cancer Center, Los Angeles, CA, Gilead Sciences, Inc.,
Abstract
ARC-9: A randomized study to evaluate etrumadenant based treatment combinations in previously treated metastatic colorectal cancer (mCRC).Org: David Geffen School of Medicine at UCLA, University of California, Los Angeles, Seoul National University Hospital, Korea University Anam Hospital, Korea University College of Medicine,
Abstract
Trop-2 mRNA expression and association with clinical outcomes with sacituzumab govitecan (SG) in patients with HR+/HER2– metastatic breast cancer (mBC): Biomarker results from the phase 3 TROPiCS-02 study.Org: Medical Oncology Group, Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Harvard Medical School, Boston, MA, Department of Medicine, Icahn School of Medicine at Mount Sinai,
Abstract
Efficacy of sacituzumab govitecan (SG) in locally advanced (LA) or metastatic urothelial cancer (mUC) by trophoblast cell surface antigen 2 (Trop-2) expression.Org: Institut de Cancérologie Gustave Roussy, Villejuif, France, France, Perlmutter Cancer Center at NYU Langone Health Medical Center, New York, NY,
Abstract
Colorectal cancer screening with blood-based tests: Estimated impact of a 1-, 2-, or 3-year screening interval compared with annual FIT and triennial mt-sDNA strategies.Org: University of Michigan, Ann Arbor, Millennium Pharmaceuticals, Division of Gastroenterology and Hepatology, Mayo Clinic, Mayo Clinic,
Abstract
How comparable are outcomes for approved PD-1/PD-L1 checkpoint inhibitors (CPI)? A model-informed drug development approach to answer the question.Org: Gilead Sciences, Inc., Foster City, CA, Certara, Inc., Princeton, NJ, Gilead Sciences Inc.,
Abstract
AURICULAR TRANSCUTANEOUS HI-FREQUENCY E-MMUNOTHERAPY SEQUENCES (ATHENS) FOR THE TREATMENT OF RHEUMATOID ARTHRITIS: 1-YEAR CHANGES IN SYNOVITIS, OSTEITIS, AND BONE EROSIONOrg: Spire Sciences, Inc, Boca Raton, United States, Clinical Research Centre, Boca Raton Regional Hospital, United States of America, Nesos Corp,